Preoperative Therapy in Melanoma: Evolving Perspectives in Clinical Trials
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preoperative Therapy in Melanoma: Evolving Perspectives in Clinical Trials
Authors
Keywords
-
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume -, Issue -, Pages 104193
Publisher
Elsevier BV
Online
2023-11-04
DOI
10.1016/j.critrevonc.2023.104193
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
- (2023) Sapna P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes
- (2022) Mary-Ann El Sharouni et al. EUROPEAN JOURNAL OF CANCER
- Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
- (2022) Oliver J. Kennedy et al. EUROPEAN JOURNAL OF CANCER
- The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
- (2022) Minke W. Lucas et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome.
- (2022) Emilia Cocorocchio et al. JOURNAL OF CLINICAL ONCOLOGY
- Delays in the surgical treatment of melanoma are associated with worsened overall and melanoma-specific mortality: A population-based analysis
- (2022) David D. Xiong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
- (2022) Irene L. M. Reijers et al. NATURE MEDICINE
- Neoadjuvant relatlimab and nivolumab in resectable melanoma
- (2022) Rodabe N. Amaria et al. NATURE
- Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?
- (2022) Hanna H. Kakish et al. Cancers
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
- (2021) E. A. Rozeman et al. NATURE MEDICINE
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- (2021) Alexander M. Menzies et al. NATURE MEDICINE
- Neoadjuvant Cytoreductive Treatment with BRAF/MEK Inhibition of prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR
- (2021) Stéphanie A. Blankenstein et al. ANNALS OF SURGERY
- Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.
- (2021) Rodabe Navroze Amaria et al. JOURNAL OF CLINICAL ONCOLOGY
- Surgeon Assessment of the Technical Impact of Neoadjuvant Systemic Therapy on Operable Stage III Melanoma
- (2021) Tina J. Hieken et al. ANNALS OF SURGICAL ONCOLOGY
- Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma
- (2021) Jeffrey S. Weber et al. EUROPEAN JOURNAL OF CANCER
- Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial
- (2021) R. Dummer et al. NATURE MEDICINE
- Efficacy of imiquimod in the management of lentigo maligna.
- (2020) Brigitte Dréno et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Ralf Gutzmer et al. LANCET
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- (2020) Reinhard Dummer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Current Immunotherapy Practices in Melanoma
- (2019) Luke D. Rothermel et al. Surgical Oncology Clinics of North America
- Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma
- (2019) John T Miura et al. Future Oncology
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
- (2018) Rodabe N Amaria et al. LANCET ONCOLOGY
- LBA42OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)
- (2018) C U Blank et al. ANNALS OF ONCOLOGY
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
- (2017) Veronica Huber et al. SEMINARS IN CANCER BIOLOGY
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
- (2016) J. Liu et al. Cancer Discovery
- Extracellular acidity strengthens mesenchymal stem cells to promote melanoma progression
- (2015) Silvia Peppicelli et al. CELL CYCLE
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary Results from a Prospective Trial of Preoperative Combined BRAF and MEK-Targeted Therapy in Advanced BRAF Mutation-Positive Melanoma
- (2015) Adam S. Johnson et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Neoadjuvant Therapy
- (2015) Howard (Jack) West et al. JAMA Oncology
- Neoadjuvant Therapy in the Treatment of Breast Cancer
- (2014) Mediget Teshome et al. Surgical Oncology Clinics of North America
- A phase 2 trial of complete resection for stage IV melanoma
- (2011) Jeffrey A. Sosman et al. CANCER
- Phase II trial of neoadjuvant temozolomide in resectable melanoma patients
- (2010) G. D. Shah et al. ANNALS OF ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells
- (2010) M L Marino et al. Cell Death & Disease
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search